Clinical Trials on B-cell Lymphoma in France

Total 4645 results

University Hospital, Caen
CNRS, UMR ISTCT 6301, LDM-TEP Groupe, GIP Cyceron, Caen, France

Completed

Dosimetry and Biodistribution of [18F]-Fludarabine in Lymphoid Malignancies (FLUDATEP)

Untreated B-Chronic Lymphocytic Leukemia or Diffuse Large B Cells Lymphoma Patients

France
Novartis Pharmaceuticals

Completed

Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data

Diffuse Large B-cell Lymphoma | Acute Lymphoblastic Leukemia (ALL)

France
University Hospital, Brest
Teva Pharmaceuticals USA

Terminated

Phase II Study Evaluating a Combination of Pegylated Liposomal Doxorubicin and Dexamethasone for the Treatment of Immunocompetent Patients With Cerebral Lymphoma Relapsed or Refractory to First-line Chemotherapy With High Dose Methotrexate (MTXHD) and / or High-dose Cytarabine. (MYLY)

Cerebral Lymphoma B Cell Refractory

France
Hospices Civils de Lyon

Not yet recruiting

Multidimensional Assessment of Quality of Life, Social and Professional Life and Care Utilization in Patients With Diffuse Large Cell B-cell Lymphoma Treated With CAR-T Cells (QUALITOP CAR-T)

Diffuse Large B-cell Lymphoma (DLBCL) | CAR-T Cells Treatment

France
Hospices Civils de Lyon

Recruiting

Quality Of Life and Drug Use in Patients With CAR-T Cells (QOLD CAR-T)

Patients With Diffuse Large B-cell Lymphoma Treated With CART-cells

France
French Innovative Leukemia Organisation

Terminated

Study of 90Y-DOTA-hLL2 as a Consolidation Therapy After R-CHOP in Patients With Diffuse Large B-cell Lymphoma

B-cell Lymphoma

France
Institut Claudius Regaud
AstraZeneca

Active, not recruiting

Single-Cell Map of Immune and Lymphoma Cells in B-cell Non-Hodgkin's Lymphoma (SIMILY)

Diffuse Large B-cell Lymphoma

France
The Lymphoma Academic Research Organisation
Roche Pharma AG

Terminated

Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia (VISMOLY)

Chronic Lymphocytic Leukemia | Primary Central Nervous System Lymphoma | Diffuse Large B-cell Lymphoma | Indolent Non-hodgkin Lymphoma

France
Centre Henri Becquerel

Not yet recruiting

Kinetics of Circulating Tumor DNA in Lymphoma Treated by Immuno-chemotherapy (LYMPHO-CLEAR)

Diffuse Large B Cell Lymphoma

France
CHU de Reims

Unknown

Multiple Fields Radiotherapy Versus Intravenous Rituximab in the Treatment of Indolent Cutaneous Lymphomas B-cell With Multiple or Recurrent Lesions (RADIO-LYMPH)

Indolent Cutaneous B Cell Lymphomas

France
Hospices Civils de Lyon

Completed

Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B-cell Lymphoma

France
Centre Antoine Lacassagne

Recruiting

18F-FDG PET Scan and MRI Diffusion.Evaluation of the Early Therapeutic Response of Diffuse Large B-cell Lymphoma (LYMPHODTECT)

Diffuse Large B Cell Lymphoma

France
The Lymphoma Academic Research Organisation

Completed

Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas

Follicular Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Mucosa Associated Lymphoid Tissue

France
Weprom

Recruiting

Secondary Prognostic Index in RefrActory Lymphoma (SPiRAL)

Diffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma

France
Fondazione Italiana Linfomi - ETS

Active, not recruiting

Indolent Non Follicular Lymphomas Prognostic Project

Indolent B-Cell Lymphomas

France, Italy, Brazil, Austria, Portugal, Ukraine
University Hospital, Montpellier

Recruiting

Is Trogocytosis a Predictive Marker of CAR-T Cell Response in Diffuse Large B-cell Lymphoma? (CARTROG)

Diffuse Large B Cell Lymphoma

France
Centre Henri Becquerel

Not yet recruiting

Real-Time Monitoring of Circulating Tumor DNA and Study of Prognostic Factors in Patients Treated With CAR-T Cells (RT-CAR)

Diffuse Large B Cell Lymphoma

France
Gustave Roussy, Cancer Campus, Grand Paris
Children's Oncology Group

Unknown

Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients

B-cell Non Hodgkin Lymphoma | Mature B-cell Leukemia Burkitt-type

Belgium, France, United Kingdom, Netherlands, Canada, Hungary, Italy, Poland, Spain, China
Hospices Civils de Lyon

Active, not recruiting

BCL6-rearrangements Implications in Non-Hodgkin Lymphomas. (BCL6-RINHL)

Follicular Lymphoma | Marginal Zone Lymphoma | Non Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma

France
University Hospital, Bordeaux

Unknown

Identification Predictive Markers of Immunochemotherapy Response to the Primary Cutaneous Diffuse Large B Cell Lymphoma (PROTEOM)

Lymphoma, Large B-Cell, Diffuse

France
Nantes University Hospital

Completed

Diffuse Large B Cell Lymphoma of the Adult: Randomization Between High Dose Chemotherapy With Rituximab and CHOP 14-Rituximab

Lymphoma, Large-Cell, Diffuse

France
Centre Hospitalier Universitaire Dijon

Not yet recruiting

Living Conditions of Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma in the Côte d'Or Region (LymphoVi)

Follicular Lymphoma | Diffuse Large Cell Diffuse Lymphoma

France
Centre Hospitalier Universitaire, Amiens
Institut Bergonié; Centre Henri Becquerel; Saint-Louis Hospital, Paris, France; Henri Mondor University Hospital and other collaborators

Recruiting

Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma (Relyage)

Chemotherapy | Elderly | Diffuse Large B-Cell Lymphoma (DLBCL), Nos

France
University Hospital, Strasbourg, France

Recruiting

B-cell Chronic Lymphoid Malignancies Markers (MALYZOMA-II)

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Hairy Cell Leukemia | Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia

France
University Hospital, Montpellier

Completed

Characterisation of TIM-3/Gal-9 Immune Checkpoints in Primary Central Nervous System Diffuse Large B Cell Lymphomas

Lymphoma, B-Cell

France
Kartos Therapeutics, Inc.

Recruiting

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma

Belgium, Korea, Republic of, United States, United Kingdom, Italy, Switzerland, Australia, France, Poland, Portugal, Czechia
Mustang Bio
National Cancer Institute (NCI)

Recruiting

Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL

Mantle Cell Lymphoma Recurrent | Mantle Cell Lymphoma Refractory | Small Lymphocytic Lymphoma, Relapsed | Waldenstrom's Macroglobulinemia Recurrent | Follicular B-cell Non-Hodgkin's Lymphoma | B-cell Lymphoma Refractory | Waldenstrom's Macroglobulinemia Refractory | Chronic Lymphoid Leukemia in Relapse

United States
Weprom
Incyte Corporation; Resilience Care

Not yet recruiting

Electronic MonitorIng of Events for dIffuse Large b Cell LYmphoma (EMILY)

Diffuse Large B Cell Lymphoma

France
Weprom

Recruiting

Impact of an APA Program on EFS in Patients With Diffuse Large-cell B Lymphoma Treated in 1st Line (PHARAOM)

Diffuse Large B Cell Lymphoma

France
Novartis Pharmaceuticals

Recruiting

Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies

B-cell Non-Hodgkin Lymphoma (B-NHL) | B-cell Acute Lymphoblastic Leukemia (B-ALL)

Japan, Italy, Spain, Belgium, Singapore, France, United States, Israel
The Lymphoma Academic Research Organisation

Active, not recruiting

Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy

Refractory Indolent Adult Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma | Diffuse Large B-Cell Lymphoma Refractory | Refractory Transformed B-cell Non-Hodgkin Lymphoma | Refractory Primary Mediastinal Large B-Cell Cell Lymphoma

France
Epizyme, Inc.

Completed

Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL

B-cell Lymphomas (Phase 1) | Advanced Solid Tumors (Phase 1) | Diffuse Large B-cell Lymphoma (Phase 2) | Follicular Lymphoma (Phase 2) | Transformed Follicular Lymphoma | Primary Mediastinal Large B-Cell Lymphoma

Australia, Canada, France, Germany, Italy, Poland, Taiwan, Ukraine, United Kingdom, United States
Lymphoma Study Association

Terminated

Efficacy Study of Rituximab After ASCT in High-Risk Diffuse Large B-Cell Lymphoma

CD20-Positive Large B-Cell Lymphoma

France
Xencor, Inc.

Terminated

Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)

Diffuse Large-cell B-cell Lymphoma

Spain, United States, France
French Innovative Leukemia Organisation

Completed

Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive Lymphomas

Diffuse Large B-Cell Lymphoma

France
Sanofi
Regeneron Pharmaceuticals

Completed

Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma

Lymphoma, Non-Hodgkin

France
Lymphoma Study Association
Bayer

Completed

Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma (ZBEAM2)

Lymphoma, Large Cell, Diffuse

France
Lymphoma Study Association
Amgen

Completed

Study of R-ACVBP Regimen Supported by Pegfilgrastim in High-Risk Diffuse Large B-Cell Lymphoma

Untreated CD20-positive Large B-cell Lymphoma

France
Genmab
AbbVie

Terminated

First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Small Lymphocytic Lymphoma | High-grade B-cell Lymphoma | Primary Mediastinal Large B-cell Lymphoma

United States, Spain, Netherlands, Belgium, France, Denmark
Gilead Sciences

Withdrawn

Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents

Diffuse Large B-Cell Lymphoma | Mediastinal B-cell Lymphoma

Italy, Spain, France, Poland
National Cancer Institute (NCI)

Completed

Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Diffuse Large B Cell Lymphoma

France
The Lymphoma Academic Research Organisation
Lymphoma Study Association

Not yet recruiting

Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse

Refractory High Grade B-Cell Lymphoma | Diffuse Large B-cell Lymphoma Refractory | Refractory Transformed B-cell Non-Hodgkin Lymphoma | Refractory Primary Mediastinal Large B-Cell Lymphoma

France
Janssen Research & Development, LLC

Terminated

A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies

Lymphoma, Follicular | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Mantle-Cell | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Leukemia, Lymphocytic, Chronic, B-Cell

United States, France, Spain, Belgium, Israel
Centre Henri Becquerel

Completed

Clinical and Prognostic Value of Sarcopenia in Patients Older Than 70 Years With Diffuse Large B-cell Lymphoma (SARCOPENIE)

Diffuse Large B Cell Lymphoma | Grade IIIB Follicular Lymphoma

France
National Cancer Institute (NCI)

Completed

Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent... and other conditions

United States
Novartis Pharmaceuticals

Recruiting

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, ALL and 1L HR LBCL

Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Small Lymphocytic Lymphoma | Large B-cell Lymphoma

Japan, Australia, Germany, Italy, Spain, France, Austria, United States
Janssen-Cilag Ltd.

Completed

A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice (FIRE)

Lymphoma, Mantle-Cell | Leukemia, Lymphocytic, Chronic, B-Cell

France
Sunesis Pharmaceuticals

Terminated

Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers

Follicular Lymphoma | Waldenstrom Macroglobulinemia | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Mantle-Cell Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma | Lymphoplasmacytoid Lymphoma

United States
Lymphoma Study Association
Fondation ARC

Completed

ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma

Lymphoma, Large-Cell, Diffuse

France, Belgium
Centre Henri Becquerel

Recruiting

Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL) (CAMIL)

Primary Mediastinal Large B-cell Lymphoma

France

Clinical Trials on B-cell Lymphoma in France

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kenya

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations